A Powerful Research and Development Engine
Explore Regeneron’s clinical pipeline
Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects the true collaborative spirit of Regeneron. The Research team discovers promising new drug candidates. From there, the Global Development team brings these investigational medicines through the full clinical development process.
Regeneron's clinical development programs span across eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
~50 investigational molecules
13 Phase 3 programs
This chart displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authority for the indications described in this section.
Filter
Ovarian cancer
Alzheimer's Disease
People with dyslipidemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Healthy volunteers
Huntington’s disease
Parkinson's Disease
Severe food allergy
Renal cell carcinoma
Prostate cancer
B-NHL
Multiple myeloma
Healthy volunteers
Solid tumors (Phase 1/2)
Multiple myeloma
Atopic Dermatitis
Obesity
Healthy volunteers
Hemophilia B
Alpha-1 Antitrypsin Disease
Transplant desensitization in patients with chronic kidney disease and lupus nephritis
Diabetic kidney disease
Metabolic dysfunction-associated steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH)
SOD1 amyotrophic lateral sclerosis (ALS)
Postural orthostatic tachycardia syndrome (POTS); Sepsis-induced hypotension
Neoadjuvant cutaneous squamous cell carcinoma (CSCC); First-line non-small cell lung cancer (NSCLC), BNT116 combination; Neoadjuvant NSCLC; Neoadjuvant hepatocellular carcinoma (HCC)
MET-altered advanced NSCLC
Perioperative NSCLC; Perioperative melanoma; First-line metastatic head and neck squamous cell carcinoma
Thrombosis
Multiple myeloma precursor and related conditions
Solid tumors
Functional hypothalamic amenorrhea
Prostate cancer
B-cell non-Hodgkin lymphoma (B-NHL) (pivotal study)
(HS-20094)
Obesity
(ALN-HSD)
Metabolic dysfunction-associated steatohepatitis (MASH)
Ovarian cancer
Pulmonary arterial hypertension (PAH)
Systemic juvenile idiopathic arthritis (sJIA) (pivotal study)
Obesity
Serous ovarian cancer; Advanced NSCLC
Stroke prevention in atrial fibrillation ("SPAF")
Birch allergy
Generalized myasthenia gravis ("gMG"), Geographic atrophy
Early-stage CSCC (intralesional)
Venous thromboembolism after total knee replacement surgery; Cancer associated VTE; Stroke prevention in atrial fibrillation ("SPAF")
Asthma in pediatrics (2–5 years of age); chronic pruritis of unknown origin (CPUO)
First-line metastatic melanoma; Adjuvant melanoma
Fibrodysplasia ossificans progressiva (FOP)
Cat allergy
Multiple myeloma (multiple lines and settings)
Generalized lipodystrophy; Monogenic obesity
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM); Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)
Lymphoma (multiple lines and settings)
Paroxysmal nocturnal hemoglobinuria ("PNH"), Geographic atrophy
SPAF
Pipeline last updated: July 30, 2026
For the latest Clinical Trials, visit ClinicalTrials.gov
Technology for now and the future
Technology drives how we discover and develop new medicines. By combining scientific expertise with our VelociSuite® technologies and advanced platforms, we accelerate innovation in drug discovery.
Explore our clinical trials
We continue advancing treatments for serious diseases.
Clinical trials help us evaluate investigational medicines and gather data to ensure they’re safe, effective, and ready for patients.